|
|
Becton Dickinson And Company (BDX) |
|
Price: $238.0100
$-0.20 
-0.084%
|
| Day's High:
| $238.47
| Week Perf:
| -0.09 %
|
| Day's Low: |
$ 236.73 |
30 Day Perf: |
1.85 % |
| Volume (M): |
67 |
52 Wk High: |
$ 266.29 |
| Volume (M$): |
$ 15,840 |
52 Wk Avg: |
$238.22 |
| Open: |
$238.61 |
52 Wk Low: |
$218.75 |
|
|
| Market Capitalization (Millions $) |
68,995 |
| Shares
Outstanding (Millions) |
290 |
| Employees |
77,000 |
| Revenues (TTM) (Millions $) |
19,828 |
| Net Income (TTM) (Millions $) |
1,412 |
| Cash Flow (TTM) (Millions $) |
3,462 |
| Capital Exp. (TTM) (Millions $) |
723 |
Becton Dickinson And Company
Becton, Dickinson and Company (BD) is a prominent global medical technology company that focuses on manufacturing and selling a wide range of medical supplies, devices, laboratory equipment, and diagnostic products. Its offerings cater to healthcare institutions, life science researchers, clinical laboratories, industry professionals, and the general public.
Business Segments
BD operates through three main business segments:
1. BD Medical: This segment encompasses various medical products, including:
- Hypodermic syringes and needles for injections.
- Insulin syringes and pen needles, as well as blood glucose monitoring systems for diabetes management.
- Infusion therapy devices, prefillable drug delivery systems, surgical instruments (blades and scalpels), and critical care systems.
- Specialty items such as anesthesia needles, ophthalmic surgery instruments, elastic support products, and thermometers.
2. BD Diagnostics: This segment focuses on diagnostics and includes:
- Clinical and industrial microbiology products.
- Sample collection and specimen management systems.
- Molecular diagnostic instruments and immunodiagnostic test kits.
- Consulting services aimed at optimizing laboratory operations.
3. BD Biosciences: This segment delivers products and systems for life sciences applications, featuring:
- Flow cytometry systems for cell analysis.
- Monoclonal antibodies aimed at biomedical research.
- Molecular biology tools for studying genes and their functions, as well as cell growth and screening solutions.
- Laboratory consumables and equipment.
International Operations
BD has a robust global presence, selling products in various regions, including Europe, Japan, Asia Pacific, Canada, and Latin America. Key products in international markets mirror those in the U.S. with a significant focus on:
- Hypodermic needles and syringes.
- Insulin syringes and pen needles.
- Diagnostic systems.
- Blood collection products (e.g. VACUTAINER' brand).
- Prefillable syringe systems (e.g. HYPAK' brand) and infusion therapy devices.
The company maintains manufacturing facilities in multiple countries, including Brazil, China, Germany, India, Japan, and the United Kingdom. However, BD acknowledges that foreign economic conditions and exchange rate fluctuations can affect the profitability of its international operations. Operating in certain countries may present risks related to local economic policies and political uncertainties.
Competition
BD faces competition from a range of specialized companies within the medical technology sector. Competitive dynamics vary across different product lines, with factors such as pricing, quality, service, brand reputation, distribution capabilities, and promotional strategies influencing market share. To maintain a competitive edge, BD invests in research, quality management, innovation, and productivity improvements across its operations.
In summary, Becton, Dickinson and Company operates as a comprehensive provider of medical technologies, supported by diverse product offerings and a significant international footprint, while navigating competitive challenges and global market dynamics.
Company Address: 1 Becton Drive, Franklin Lakes, 7417 NJ
Company Phone Number: 847-6800 Stock Exchange / Ticker: NYSE BDX
|
|
|
Customers Net Income fell by |
BDX's Customers Net Profit Margin fell to |
-12.67 % |
2.99 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Becton Dickinson And Company
The financial results of Becton Dickinson and Company for the most recent fiscal period have shown some promising developments. The company reported a 20.92% increase in profits per share, which is a strong indicator of its financial health and growth potential. Additionally, the Income per Share soared by an impressive 92.71%, demonstrating significant improvement in the company's bottom line.
While the revenue increased moderately by 4.646%, it fell short of the industry average by 6.12%. This indicates that Becton Dickinson And Company may be facing some challenges in increasing its top-line growth compared to its competitors. However, the company's net earnings saw a healthy increase of 16.49%, showing that it is effectively managing its expenses and maximizing its profits.
|
| Becton Dickinson And Company
In the first quarter of 2024, Becton Dickinson And Company experienced a revenue growth of 2.617%, reaching $4.71 billion. However, this increase was not enough to prevent a significant income contraction of -43.53% compared to the same period the previous year. Earnings per share (EPS) stood at $0.96.
While the company's revenue showed growth, it fell short of the 14.22% surge reported by most companies in the Medical Equipment & Supplies sector during the first quarter of 2023. In contrast, the EPS more than doubled by 161.72% to $0.96 per share, but revenue deteriorated by -7.49% to $5.09 billion in comparison to the prior reporting period.
Net earnings in the most recent fiscal period declined by -44.79% to $281.000 million compared to $509.000 million in the corresponding period a year before. Becton Dickinson And Company focused on improving sales in the most recent fiscal period, leading to a decrease in net margin to 5.97%.
As a result of the seasonal nature of the business, inventories decreased to $3,273.0 million in the first quarter of 2024 compared to the previous quarter, but this marked an increase relative to the same period a year ago.
Operating earnings fell -24.96% to $439 million, causing Becton Dickinson And Company's operating margin to decline to 9.33% from 12.76% in the first quarter of 2023. The buildup in accounts receivable is a strong signal of rising demand, as accounts receivables were valued at $2,534.0 million, higher than the preceding quarterOver the past 3 months, Becton Dickinson And Company shares experienced a decline of -3.68%, while in the preceding month, BDX shares went down by -1.25%. Currently, the company's shares trade only 6% above its 52-week low.
|
| Becton Dickinson And Company
Becton Dickinson And Company, a medical equipment and supplies company, recently released its financial results for the fourth quarter of 2023. The company reported an income per share of $0.37 and revenue of $4.88 billion during this period. While the revenue increased by 20.459% compared to the fourth quarter of 2022, the company's income per share declined from $0.92 to $0.37. This indicates that although Becton Dickinson And Company saw significant revenue growth, their profitability decreased.
However, when compared to other companies in the Medical Equipment & Supplies sector, Becton Dickinson And Company had a much higher top-line improvement during the fourth quarter of 2023. On average, companies in this sector reported a top-line improvement of 4.80% in comparison to the same period in 2022. In contrast, Becton Dickinson And Company experienced a revenue surge of 20.459%. This suggests that the company outperformed its industry peers in terms of revenue growth.
|
| Becton Dickinson And Company
Becton Dickinson And Company (BDX) has shown strong financial performance in its most recent fiscal period, with significant growth in revenue and income. The company reported a 5.107% increase in revenue to $4.88 billion compared to the prior year quarter, outperforming its sector peers in the Medical Equipment & Supplies industry, which only saw 1.52% revenue growth during the same period. Comparatively, BDX's earnings also advanced by 15.25% to $1.36 per share, surpassing the previous year's quarter earnings of $1.18 per share.
BDX's net profits for the most recent fiscal period amounted to $407.000 million, a notable increase of 12.74% from the net earnings of $361.000 million reported in the same fiscal period a year ago. While the operating margin fell to 11.25% in the most recent fiscal period, the net margin improved to 8.34%, indicating improved profitability for the company.
|
| Per Share |
Current |
| Earnings (TTM) |
4.86 $ |
| Revenues (TTM) |
68.4 $
|
| Cash Flow (TTM) |
11.94 $ |
| Cash |
5.14 $
|
| Book Value |
88.99 $
|
| Dividend (TTM) |
3.77 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
4.86 $
|
| Revenues (TTM) |
68.4 $ |
| Cash Flow (TTM) |
11.94 $ |
| Cash |
5.14 $
|
| Book Value |
88.99 $ |
| Dividend (TTM) |
3.77 $ |
|
|
|
|
4.24% 